CTLA4 and metastatic melanoma: With the recent approval of anti-LAG-3 for the treatment of late-stage metastatic melanoma, identification of biomarkers that can inform on prescription of monotherapy anti-PD-1, versus combinations that include anti-CTLA-4 and LAG-3, are urgently needed.